Skip to content

Study · Measured the body's own peptide · 2014

1 result

Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry.

Le Faouder J, Laouirem S, Alexandrov T, Ben-Harzallah S, Léger T, Albuquerque M, Bedossa P, Paradis V

Proteomics1 Apr 2014Cited by 19 (Europe PMC)

PMID24678008 (opens in a new tab)DOI10.1002/pmic.201300463 (opens in a new tab)PepBankPUB-24678008
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In human cholangiocarcinoma, thymosin β4 was diffusely overexpressed in peripheral-type tumours, one of the protein differences between peripheral and hilar subtypes.

    In plain wordsIn bile duct cancer tissue, the body's own thymosin β4 was found at higher levels in peripheral-type tumours.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTβ4 expression in peripheral cholangiocarcinoma
    Study

    n = 27

    Comparator
    Hilar cholangiocarcinoma
    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    In P-CC, thymosin β4 was diffusely overexpressed.
    1 context sentence
    Summary · context
    Twenty-seven CC (16 P-CC and 11 H-CC) were subjected to MALDI IMS.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.